Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study

Gruzelle, Vianney; Guet-Revillet, Hélène; Segonds, Christine; Bui, Stéphanie; Macey, Julie; Chiron, Raphaël; Michelet, Marine; Murris-Espin, Marlène; Mittaine, Marie

doi:10.1186/s12890-020-01190-y

Table 2 Individual characteristics, treatments and outcomes in 17 cases of Burkholderia primary colonisation

From: Management of initial colonisations with Burkholderia species in France, with retrospective analysis in five cystic fibrosis Centres: a pilot study

Patient No.	Centre	Burkholderia Species	Co-pathogens	Age (years)	FEV1% at PC	Treatment (molecules, routes of administration and duration)	Consistency antibiogram/ antibiotic therapy^a	Outcome
1	M	B. multivorans	MRSA, PA	19	71	PO Levofloxacin and Cotrimoxazole 21 days; INH Aztreonam 28 days	Yes (3/3)	Eradication
2	M	B. multivorans	MRSA, PA, Fungi^e	23	79	PO Cotrimoxazole; INH Aztreonam, 28 days	Yes (2/2)	Eradication
3	M	B. multivorans	MSSA, Fungi^e	28	94	IV Ceftazidime and Tobramycin, 14 days	No (1/2)	Persistence
4^b	B	B. multivorans	MRSA	13	31	IV Ceftazidime and Gentamicin, 14 days	No (1/2)	Persistence
5	T	B. multivorans		6	113	Not treated		Eradication^c
6	T	B. multivorans	MSSA, PA, Fungi^e	21	105	Not treated		Persistence
7	T, B	B. cenocepacia IIIA	MRSA, Sten	10	87	IV Ceftazidime and Ciprofloxacin, 14 days	Yes (2/2)	Eradication^c
8	M	B. cenocepacia IIIB	Sten, MB	18	52	PO Ciprofloxacin; INH Aztreonam, 28 days	No (0/2)	Eradication^c
9	T	B. cenocepacia IIIA	MRSA PA	19	59	IV Piperacillin-tazobactam and Ciprofloxacin, 14 days	No (1/2)^d	Persistence
10	M	B. cenocepacia IIIA	PA	22	62	IV Temocillin and Tobramycin, 14 days; PO Cotrimoxazole, 28 days	Yes (2/3)	Persistence
11	M	B. contaminans	PA, MB	33	26	Not treated		Eradication^c
12	T, M	B. vietnamiensis	MSSA	17	109	Not treated		Eradication
13	B	B. ambifaria	MSSA	7	83	IV Ceftazidime and Tobramycin, 14 days	No (1/2)	Persistence
14	T	Unidentified BCC	MSSA	16	106	IV Ceftazidime and Ciprofloxacin; INH Tobramycin, 14 days	Yes (3/3)	Eradication^c
15	B	B. gladioli	MSSA	14	112	IV Piperacillin-tazobactam; INH Tobramycin, 14 days	Yes (2/2)	Eradication
16	T	B. gladioli	Sten	34	99	Not treated		Eradication
17	T	B. gladioli	MSSA, Fungi^e	32	65	Not treated		Persistence

FEV1 Forced Expiratory Volume in one second, B Bordeaux, M Montpellier, T Toulouse, BCC Burkholderia cepacia complex, MB Mycobacteria, MSSA, Methicillin-Susceptible Staphylococcus aureus, MRSA Methicillin-Resistant Staphylococcus aureus, PA Pseudomonas aeruginosa, Sten Stenotrophomonas maltophilia, PO per os, IV intravenous, INH inhaled
^a Consistency antibiogram/antibiotic therapy: in vitro full susceptibility to at least two of the antibiotics used, or to at least one antibiotic if combined with inhaled tobramycin. All BCC were resistant to IV aminoglycosides (natural resistance)
^b This patient underwent lung transplantation and colonisation disappeared following surgery
^c Single isolate
^d The strain was only susceptible to ciprofloxacin
^e Concerning fungi repartition: patient No 2 Aspergillus fumigatus; Patient No 3 Aspergillus spp.; Patient No 6 Candida albicans; Patient No 17 Aspergillus fumigatus and Candida albicans

Back to article page

ISSN: 1471-2466

Contact us

Submission enquiries: bmcpulmonarymedicine@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Pulmonary Medicine

Contact us